ANI Pharmaceuticals

Expanding ACTH Potential And Rare Disease Markets Will Evolve

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

15 Sep 24

Updated

10 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

35.9%

7D

-2.7%

Loading

1Y

35.9%

7D

-2.7%

You can edit this narrative until Nov 11 10:10 AM. Then, changes will post as Updates.

Author's Valuation

US$109.8827.4% undervalued

AnalystConsensusTarget Fair Value

Shared on 10 Nov 25

Fair value Increased 4.64%

ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities

Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.

Shared on 25 Sep 25

Fair value Increased 6.06%

ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.

Shared on 10 Aug 25

Fair value Increased 22%

Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.

Shared on 01 May 25

Fair value Decreased 9.69%

Shared on 23 Apr 25

Fair value Increased 0.47%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.41%

AnalystConsensusTarget has increased profit margin from 5.3% to 10.8% and decreased future PE multiple from 49.2x to 23.6x.

Shared on 11 Mar 25

Fair value Decreased 1.62%

AnalystConsensusTarget has decreased profit margin from 10.5% to 5.3% and increased future PE multiple from 17.8x to 49.2x.

AnalystConsensusTarget Fair Value

US$109.88

27.4% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

8.14%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$103.74m

Earnings '28

x

32.40x

PE Ratio '28

=

US$3.36b

Market Cap '28

US$3.36b

Market Cap '28

/

25.61m

No. shares '28

=

US$131.24

Share Price '28

US$131.24 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$107.26

Fair Value '25